Prime Capital Investment Advisors LLC Decreases Holdings in Pfizer Inc. (NYSE:PFE)

Prime Capital Investment Advisors LLC reduced its holdings in shares of Pfizer Inc. (NYSE:PFE) by 4.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 170,314 shares of the biopharmaceutical company’s stock after selling 8,731 shares during the period. Prime Capital Investment Advisors LLC’s holdings in Pfizer were worth $4,929,000 at the end of the most recent reporting period.

Several other large investors have also recently made changes to their positions in PFE. China Universal Asset Management Co. Ltd. bought a new position in shares of Pfizer in the 1st quarter worth approximately $315,000. GSA Capital Partners LLP bought a new position in Pfizer in the first quarter worth $439,000. Koshinski Asset Management Inc. lifted its position in Pfizer by 20.5% during the first quarter. Koshinski Asset Management Inc. now owns 24,265 shares of the biopharmaceutical company’s stock valued at $673,000 after buying an additional 4,130 shares during the period. Dearborn Partners LLC boosted its holdings in shares of Pfizer by 18.4% during the 1st quarter. Dearborn Partners LLC now owns 32,683 shares of the biopharmaceutical company’s stock valued at $907,000 after buying an additional 5,077 shares in the last quarter. Finally, Private Management Group Inc. grew its position in shares of Pfizer by 270.7% in the 1st quarter. Private Management Group Inc. now owns 26,579 shares of the biopharmaceutical company’s stock worth $738,000 after buying an additional 19,409 shares during the period. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Stock Performance

Shares of PFE opened at $26.18 on Wednesday. The firm has a market capitalization of $148.36 billion, a P/E ratio of 35.38, a PEG ratio of 0.83 and a beta of 0.67. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. Pfizer Inc. has a one year low of $25.20 and a one year high of $31.54. The business has a fifty day moving average of $28.84 and a 200 day moving average of $28.67.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The business had revenue of $17.70 billion during the quarter, compared to the consensus estimate of $14.92 billion. During the same period in the previous year, the company posted ($0.17) EPS. The business’s quarterly revenue was up 31.2% compared to the same quarter last year. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.96 EPS for the current year.

Pfizer Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 2nd. Stockholders of record on Friday, November 8th will be paid a dividend of $0.42 per share. This represents a $1.68 annualized dividend and a dividend yield of 6.42%. The ex-dividend date is Friday, November 8th. Pfizer’s dividend payout ratio is presently 227.03%.

Insider Activity

In related news, Director Scott Gottlieb purchased 1,000 shares of Pfizer stock in a transaction on Wednesday, October 30th. The stock was acquired at an average price of $28.24 per share, for a total transaction of $28,240.00. Following the completion of the transaction, the director now directly owns 10,000 shares in the company, valued at $282,400. This represents a 0.00 % increase in their position. The purchase was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.06% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms recently commented on PFE. Sanford C. Bernstein initiated coverage on shares of Pfizer in a research note on Thursday, October 17th. They set a “market perform” rating and a $32.00 price objective on the stock. Wells Fargo & Company upped their price target on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 31st. Daiwa America raised Pfizer from a “moderate buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th. UBS Group raised their price target on Pfizer from $30.00 to $31.00 and gave the company a “neutral” rating in a report on Wednesday, July 31st. Finally, Evercore ISI upgraded shares of Pfizer to a “strong-buy” rating in a research note on Wednesday, October 30th. Eight research analysts have rated the stock with a hold rating, five have given a buy rating and three have given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Pfizer presently has a consensus rating of “Moderate Buy” and a consensus price target of $33.58.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.